Roche stresses careful AI token use and pauses drug from Carmot acquisition

Roche's CEO Thomas Schinecker said the company is adopting a thoughtful approach to how it employs AI tokens, emphasizing responsible use.

He noted that AI tools have already helped increase the number of new molecules in Roche's pipeline, marking a significant boost in discovery efforts.

At the same time, Roche decided to shelve a drug that was part of its recent purchase of Carmot, indicating a cautious stance on integrating assets from the acquisition.

The company's comments suggest it will continue to leverage AI while closely monitoring the implications of token‑based technologies and acquisition‑derived projects.